Takeda Pharmaceutical
282 hedge funds and large institutions have $799M invested in Takeda Pharmaceutical in 2022 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 87 increasing their positions, 88 reducing their positions, and 39 closing their positions.
722% more call options, than puts
Call options by funds: $39.1M | Put options by funds: $4.76M
6% more capital invested
Capital invested by funds: $753M → $799M (+$46.3M)
3% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 39
0.04% more ownership
Funds ownership: 3.56% → 3.6% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 88
2% less funds holding
Funds holding: 287 → 282 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$56M |
| 2 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$24.8M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$12.4M |
| 4 |
VanEck Associates
New York
|
+$12.3M |
| 5 |
Renaissance Technologies
New York
|
+$11.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$36.3M |
| 2 |
BlackRock
New York
|
-$12M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.68M |
| 4 |
Goldman Sachs
New York
|
-$8.68M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.48M |
TAK Hedge Fund Activity: Q2 2022 in Review
282 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q2 2022, worth a combined $799M — up 6.1% from $753M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new TAK positions and 39 closed out — a net gain of 1 holder — while 87 added to existing stakes and 88 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $56M. The largest seller was Bank of America, cutting an estimated $36.3M.
- 282 institutional investors held Takeda Pharmaceutical (TAK) as of Q2 2022, down from 287 in Q1 2022.
- Funds reported $799M of Takeda Pharmaceutical stock for Q2 2022, up 6.1% quarter-over-quarter.
- 40 funds opened new Takeda Pharmaceutical positions in Q2 2022 and 39 closed out, a net change of +1 holder.
- The largest Takeda Pharmaceutical buyer in Q2 2022 was Morgan Stanley, an estimated $56M added.
- The largest Takeda Pharmaceutical seller in Q2 2022 was Bank of America, an estimated $36.3M sold.
Based on aggregated 13F filings for Q2 2022.